Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Tuesday 28 September, 2021

Tissue Regenix Group

Holding(s) in Company

RNS Number : 1345N
Tissue Regenix Group PLC
28 September 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B5SGVL29

Issuer Name

TISSUE REGENIX GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Harwood Capital Management (Gibraltar) Limited

City of registered office (if applicable)

Gibraltar

Country of registered office (if applicable)

Gibraltar

Name

City of registered office

Country of registered office

Harwood Capital LLP



4. Details of the shareholder

Name

City of registered office

Country of registered office

Harwood Capital LLP



Oryx International Growth Fund Limited



5. Date on which the threshold was crossed or reached

21-Sep-2021

6. Date on which Issuer notified

27-Sep-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.020000

0.000000

7.020000

493822756

Position of previous notification (if applicable)

6.930000

0.000000

6.930000

484822756

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B5SGVL29

450000000


6.400000


GB00B5SGVL29

43822756


0.620000


Sub Total 8.A

493822756

7.020000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights






Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights







Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

Oryx International Growth Fund Limited

6.400000



Christopher Harwood Bernard Mills

Harwood Capital LLP

0.620000



10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

27-Sep-2021

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUBSBRAOUKUAR

a d v e r t i s e m e n t